EIF4EBP1 and cancer: Moreover, allosteric mTOR inhibitors can modestly reduce phosphorylated 4E-BP1 levels by inhibiting its phosphorylation and, as a result, are unable to effectively inhibit eIF4E-mediated cap-dependent translation initiation in human cancers, including head and neck squamous-cell carcinomas [9,20].